1. Introduction {#sec1}
===============

Lung cancer, as one of the most frequently occurring cancers in the world, is always the leading cause of cancer-related death among both men and women \[[@B1]\]. Approximately two million people are diagnosed with lung cancer each year and most of them diagnosed at an advanced stage \[[@B2]\]. The lack of effective treatment options and high mortality make lung cancer a major public health challenge all over the world \[[@B3], [@B4]\]. With the advent of next-generation genotyping and in-depth understanding of the molecular biology of lung cancer, genotyping of single-nucleotide polymorphisms (SNPs) may be pivotal in the personalized treatment for patients with lung cancer \[[@B5]\].

Angiogenesis refers to the complex process of the formation of new networks of blood vessels. Increased angiogenesis has been proved to be associated with the process of tumor growth and metastasis \[[@B6]\]. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor, is one of the most vital regulators of angiogenesis and vascular permeability. It is well known that VEGF plays a critical role in the progress and prognosis of malignancy \[[@B7], [@B8]\], which has been confirmed*in vitro and in vivo*\[[@B9], [@B10]\]. Serum VEGF levels of cancer patients were significantly higher than those of healthy controls \[[@B11]\]. Moreover, serum VEGF levels always can predict the effects of chemoradiotherapy sensitivity in cancer patients \[[@B12]\]. In lung cancer, VEGF is important in establishing a vascular supply within the tumor \[[@B13]\]. The VEGF/VEGF-receptor axis is composed of multiple ligands and receptors with overlapping and distinct ligand--receptor binding specificities, cell-type expression, and function \[[@B14]\]. Targeted inhibition of the VEGF signaling pathway can partially suppress tumor angiogenesis and growth. In recent years, the use of anti-VEGF antibodies, such as bevacizumab, has shown a favorable clinical efficacy in treating non-small cell lung cancer (NSCLC), especially when used in combination with chemotherapy \[[@B15], [@B16]\].

The VEGF gene is located at chromosome 6p21.3, covering 14 kb in length with 8 exons and 7 introns \[[@B17]\]. Being highly polymorphic, at least 30 single SNPs have been identified and described \[[@B18]\]. Several SNPs of VEGF have been reported to be associated with individual susceptibility to cancer and can alter the VEGF expression and protein production \[[@B19], [@B20]\]. For example, −634G\>C SNP in the 5′-UTR of VEGF affects the protein translation efficiency, and 936C\>T SNP in the 3′-UTR influences the expression of VEGF in tumor tissues \[[@B21], [@B22]\]. SNPs, such as VEGF -2578C/A, +936C/T, and -460C/T, have been reported to be associated with cancer susceptibility, tumor growth, and radiotherapy sensitivity in patients with lung cancer \[[@B23], [@B24]\]. Recently, accumulating evidence has shown that VEGF aberrations may contribute to the development of lung cancer \[[@B25]\]. However, due to the limited sample size, the results of these studies remain controversial or inconclusive. In recent years, related studies were updated; in particular a study included in a previous meta-analysis was withdrawn \[[@B26]\]. Thus, this updated meta-analysis including all eligible case--control studies was performed to investigate whether VEGF polymorphisms were associated with the risk of lung cancer.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy and Selection Criteria {#sec2.1}
-------------------------------------------

A systematic literature search was conducted on PubMed, Embase, and Web of Science databases until October 1, 2017, to identify studies for inclusion in the meta-analysis. The relevant key words and search strategies were as follows: "vascular endothelial growth factor" or "VEGF," "polymorphisms" or "mutation," "variants" and "lung cancer," "non-small cell lung cancer," or "NSCLC." These terms were arranged into different combinations when used for the search. Besides, the reference lists of original studies were searched manually for additional literature. All the eligible studies were checked carefully to prevent overlapping datasets, and only previously published studies were included.

The studies that fulfilled the following criteria were considered eligible: (1) studies focused on the association between VEGF and the risk of lung cancer; (2) studies used a case--control or cohort design; and (3) inclusion of sufficient data on the frequency of genotypes including ORs and their 95% CIs. In addition, the studies that did not meet the aforementioned inclusion criteria were excluded.

2.2. Data Extraction {#sec2.2}
--------------------

The data were independently extracted from all the eligible studies by two investigators (Yang FM and Qin ZQ) according to the aforementioned inclusion criteria. When it came to conflicting evaluations, an agreement was settled after discussion with the third reviewer. For each study, the extracted information included: the surname of the first author, year of publication, ethnicity, source of controls, sample size of case and control groups, SNP genotyping methods, genotype distributions, and the results of the Hardy--Weinberg equilibrium (HWE) test.

2.3. Statistical Analysis {#sec2.3}
-------------------------

The pooled odds ratios (ORs) and their corresponding 95% CIs were calculated to evaluate the strength of association between VEGF gene polymorphisms and lung cancer risk under five genetic models: allele model, homozygous model, heterozygous model, dominant model, and recessive model. The genotypic distributions of different polymorphic sites in the subjects were compared with those expected under HWE using the chi-squared goodness-of-fit test, and a*P* value \<0.05 was considered to indicate statistically significant heterogeneity.

The pooled ORs were calculated using the fixed-effects model or the random-effects model according to the presence (*P* \< 0.05) or absence (*P* \> 0.05) of heterogeneity. When the*P*value was \>0.05, the pooled ORs were calculated using the fixed-effects model based on the Mantel--Haenszel method. Otherwise, the random-effects model with the DerSimonian--Laird method was used for this meta-analysis. Then, the sources of heterogeneity were further analyzed according to ethnicity. The sensitivity analysis was performed by sequentially excluding individual studies to evaluate the stability and reliability of the results. In addition, publication bias between the studies was analyzed using Begg\'s funnel plots and Egger\'s linear regression tests. All the aforementioned statistical tests were performed using Stata12.0 software.

3. Results {#sec3}
==========

3.1. Studies Characteristics {#sec3.1}
----------------------------

According to the searching criteria, a total of 109 studies were initially identified through a primary search of PubMed, Embase, and Web of Science databases and reference lists. Among these studies, 13 full-text studies met the inclusion criteria and were included in the present meta-analysis for further evaluation, which were accrued between December 1992 and July 2012 \[[@B27]--[@B39]\]. Besides, all studies suggested that the distribution of genotypes in the controls was consistent under HWE. The flowchart of literature search and selection procedure is shown in [Figure 1](#fig1){ref-type="fig"}. The baseline characteristics of the studies associated with the risk of lung cancer are comprehensively listed in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}. Among these 13 enrolled studies, 10 were based on Asian populations and 3 on Caucasian populations.

3.2. Quantitative Synthesis Results {#sec3.2}
-----------------------------------

Overall, the strength of association between VEGF genetic polymorphisms and lung cancer risk was evaluated using the pooled ORs with 95% CIs based on five genetic comparison models. A summary of all the meta-analysis results for the 13 studied VEGF polymorphisms and lung cancer susceptibility is provided in [Table 3](#tab3){ref-type="table"}.

3.3. +936C/T and Lung Cancer Risk {#sec3.3}
---------------------------------

In the present meta-analysis, the combined results of all analyses showed that the pooled OR of nine studies was 1.11 (95% CI: 0.89--1.38,*P* \< 0.001) for the allele model, 1.32 (95% CI: 0.86--2.04,*P* = 0.047) for the homozygote model, 1.11 (95% CI: 0.86--1.42,*P* \< 0.001) for the heterozygote model, 1.12 (95% CI: 0.87--1.46,*P* \< 0.001) for the dominant model, and 1.25 (95% CI: 0.94--1.65,*P* = 0.266) for the recessive model, indicating no association between VEGF +936C/T mutation and lung cancer susceptibility ([Figure 2](#fig2){ref-type="fig"}). Furthermore, subgroup analyses by ethnicity and source of control were performed to establish the effects of heterogeneity on the results. In the subgroup analyses by ethnicity and source of control, no significant results were found in all genetic comparison models ([Table 3](#tab3){ref-type="table"}).

3.4. -460C/T and Lung Cancer Risk {#sec3.4}
---------------------------------

The results demonstrated that the VEGF -460C/T polymorphism was not significantly correlated with the risk of lung cancer only in the allele model (pooled OR = 1.04, 95% CI: 0.97--1.12,*P* = 0.201), homozygote model (pooled OR = 1.12, 95% CI: 0.96--1.30,*P* = 0.269), heterozygote model (pooled OR = 1.11, 95% CI: 0.96--1.28,*P* = 0.687), dominant model (pooled OR = 1.11, 95% CI: 0.97--1.27,*P* = 0.534), and recessive model (pooled OR = 1.02, 95% CI: 0.92--1.13,*P* = 0.151) ([Figure 3](#fig3){ref-type="fig"}). When the studies were stratified by ethnicity, significant differences were observed in Asian populations in these models (allele model: pooled OR = 1.12, 95% CI: 1.00--1.26; homozygote model: pooled OR = 1.51, 95% CI: 1.12--2.03), but no significant results were detected in Caucasian populations. Furthermore, significant results were found in the homozygote model (pooled OR = 1.59, 95% CI: 1.11--2.29) in the subgroup analysis by the source of control ([Table 3](#tab3){ref-type="table"}).

3.5. -2578C/A and Lung Cancer Risk {#sec3.5}
----------------------------------

The combined results of all analyses showed that the pooled OR of these studies was 1.12 (95% CI: 0.87--1.43,*P* \< 0.001) for the allele model, 1.15 (95% CI: 0.71--1.86,*P* = 0.037) for the homozygote model, 1.33 (95% CI: 0.66--2.68,*P* \< 0.001) for the heterozygote model, 1.33 (95% CI: 0.74--2.40,*P* \< 0.001) for the dominant model, and 0.98 (95% CI: 0.52--1.84,*P* \< 0.001) for the recessive model, indicating no significant association between VEGF -2578C/A polymorphism and lung cancer risk ([Figure 4](#fig4){ref-type="fig"}). In addition, when the studies were stratified by ethnicity and source of control, no significant differences were found in all genetic models ([Table 3](#tab3){ref-type="table"}).

3.6. Sensitivity Analysis {#sec3.6}
-------------------------

Individual studies were consecutively omitted in the sensitivity analysis to detect the influence of each study on the pooled OR. The sensitivity analysis for the results of VEGF genetic polymorphisms and lung cancer risk demonstrated that the obtained results were statistically robust, and no individual study affected the pooled OR significantly ([Figure 5](#fig5){ref-type="fig"}).

3.7. Publication Bias {#sec3.7}
---------------------

The possible publication bias of the studies involved in the present meta-analysis was examined via Begg\'s funnel plot and Egger\'s test. As shown in [Figure 6](#fig6){ref-type="fig"}, the shapes of funnel plots showed no evidence of publication bias in the dominant model (+936C/T,*P* = 0.754; -460C/T,*P* = 0.133; -2578C/A,*P* = 0.230). Result from Begg\'s test and Egger\'s test also confirmed the absence of publication bias. Considering the above tests, the results of our meta-analysis were reliable.

4. Discussion {#sec4}
=============

As an important regulator of various malignancy angiogenesis, VEGF is always involved in the development and progression of multiple cancers \[[@B25]\]. The process of carcinogenesis is accelerated when the VEGF gene expression is influenced by some molecular biology variations \[[@B40]\]. Previous studies have identified at least 30 SNPs of VEGF \[[@B18]\]. Some of these have been confirmed to be associated with individual susceptibility to various types of cancers, including lung cancer \[[@B41], [@B42]\]. In the last two decades, many case--control studies have assessed the association of VEGF polymorphisms with the risk of lung cancer. However, due to the limited sample size and other reasons, the findings are controversial or ambiguous \[[@B27]--[@B39]\]. In addition, a recent meta-analysis suggested that VEGF -2578C/A polymorphism was capable of increasing the susceptibility to lung cancer, especially among smokers and patients with lung squamous cell carcinoma. Additionally, for +936C/T polymorphism, increased lung cancer susceptibility was observed only among patients with lung adenocarcinoma. In contrast, VEGF -460C/T polymorphism might be a protective factor among nonsmokers and patients with SCC \[[@B43]\]. However, several other studies showed that the -460C/T and -2578C/A polymorphisms of VEGF were not associated with an increased risk of lung cancer \[[@B44]--[@B46]\]. The conclusion in previous studies was still inaccurate due to limited published data and lack of subgroup analysis. Therefore, this updated meta-analysis including all eligible case--control studies was performed to investigate these associations.

This meta-analysis included 13 independent case--control studies with a total of 4477 patients with lung cancer and 4346 healthy controls to investigate the correlation between VEGF variants and the risk of lung cancer. The results of our meta-analysis showed that VEGF +936C/T, -460C/T, and -2578C/A gene polymorphisms were not associated with the risk of lung cancer. However, the conclusion was still inaccurate due to limited published data. Furthermore, the predictive value of VEGF polymorphisms in the prognosis of lung cancer could not be assessed. The sample size in the present meta-analysis was larger than that in any individual study, leading to more precise and robust results. Thus, the present meta-analysis aimed to provide a more powerful and reliable conclusion about the relationship between VEGF genetic polymorphisms and lung cancer risk. Moreover, no statistically significant association was detected between VEGF +936C/T, -460C/T, and -2578C/A polymorphisms and lung cancer risk in all genetic comparison models. Interestingly, the VEGF +460T/C polymorphism was found to be significantly associated with the susceptibility to lung cancer only in Asian populations. Although the exact mechanism underlying ethnic differences was unknown, the possible reasons could be the natural selection pressures or a balance by other related functional genetic variants and environmental exposures, resulting in gene polymorphisms \[[@B47]\]. Each polymorphism alone may be insufficient to influence the susceptibility to lung cancer.

However, the present meta-analysis had several limitations. First, the number of included studies in our meta-analysis was not so abundant, leading to limited statistical precision, especially in subgroup analysis. Hence, more studies using standardized unbiased methods are needed to offer more detailed individual data. Second, the population included in this meta-analysis is mainly limited to Asian and Caucasian ethnicities, and more data from other ethnic groups will be required. Third, since only data from previously published studies were included in the meta-analysis, it was possible that some related published studies or unpublished studies had null results, resulting in a deviation from the expected results. Finally, tumorigenesis is a complex process involved in the regulation of a series of genetic factors besides VEGF. As a multifactorial disease, the risk of developing lung cancer was closely related to the environment, smoking, occupational exposure, and interaction among various genetic factors, and not just a single factor. Therefore, more raw data are needed to adjust other variables, such as age, sex, and smoking. Consequently, further high-quality studies on the risk of lung cancer should be conducted over the next few years to achieve more accurate results.

5. Conclusions {#sec5}
==============

In sum, this meta-analysis found that VEGF +936C/T, -460C/T, and -2578C/A polymorphisms were not associated with the susceptibility to lung cancer. Interestingly, the VEGF +460T/C polymorphism might be a risk factor for lung cancer only in Asian populations. Based on our discovery, additional large population-based multicenter prospective studies are needed to confirm the association of VEGF**gene polymorphisms** and lung cancer risk.
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###### 

Baseline characteristics of studies associated with the risk of lung cancer included in the meta-analysis.

  Year   Surname    Ethnicity   Country     SOC   Genotyping   Cases   Controls   Gene polymorphism
  ------ ---------- ----------- ----------- ----- ------------ ------- ---------- ----------------------------
  2017   Yamamoto   Japan       Asian       HB    TaqMan       462     379        -460C/T
  2017   Naikoo     India       Asian       PB    PCR-RFLP     112     116        +936C/T
  2017   Naykoo     India       Asian       PB    PCR-RFLP     199     401        +936C/T, -2578C/A
  2015   Krupnova   Belarus     Caucasian   HB    PCR-RFLP     202     336        +936C/T, -2578C/A
  2015   Liu        China       Asian       PB    PCR-RFLP     414     338        -460C/T, -2578C/A
  2014   Deng       China       Asian       HB    PCR-RFLP     65      110        -2578C/A
  2013   Sun        China       Asian       PB    PCR-RFLP     126     160        -460C/T
  2013   de Mello   Portugal    Caucasian   HB    MassARRAY    144     144        +936C/T, -460C/T, -2578C/A
  2012   Naik       India       Asian       PB    PCR-RFLP     100     150        +936C/T
  2012   Li         China       Asian       PB    PCR-RFLP     150     150        +936C/T, -2578C/A
  2009   Liang      China       Asian       PB    PCR-RFLP     171     172        +936C/T, -2578C/A
  2008   Zhai       America     Caucasian   HB    TaqMan       1900    1458       +936C/T, -460C/T
  2005   Lee        Korea       Asian       PB    PCR-RFLP     432     432        +936C/T, -460C/T

SOC: source of control; HB: hospital-based; PB: population-based controls.

###### 

The genotype frequency data of individual studies included in the meta-analysis.

  ------ ----------- ---------- --------- ---------- ----- ------------- ------ ----- ----- -----
  VEGF   rs3025039   +936C/T              Case (n)         Control (n)                      
                                                                                            
  Year   Surname     Case       Control   CC         CT    TT            CC     CT    TT    HWE
                                                                                            
  2017   Naikoo      109        112       68         32    9             65     38    9     Y
  2017   Naykoo      199        401       80         99    20            261    120   20    Y
  2015   Krupnova    161        360       115        38    8             267    80    13    N
  2013   de Mello    144        144       115        28    1             111    30    3     Y
  2012   Naik        90         150       54         28    8             80     48    22    N
  2012   Li          150        150       108        35    7             114    33    3     Y
  2009   Liang       171        172       123        40    8             131    38    3     Y
  2008   Zhai        1900       1458      1441       424   35            1125   308   25    Y
  2005   Lee         432        432       281        137   14            266    154   12    Y
                                                                                            
  VEGF   rs833061    -460C/T                                                                
                                                                                            
  2017   Yamamoto    462        379       32         197   233           35     157   187   Y
  2015   Liu         414        338       21         164   229           23     138   177   Y
  2013   Sun         126        160       22         43    61            38     69    53    Y
  2013   de Mello    144        144       28         79    37            31     72    41    Y
  2008   Zhai        1900       1458      439        922   539           342    694   422   Y
  2005   Lee         430        432       18         184   228           27     168   237   Y
                                                                                            
  VEGF   rs699947    -2578C/A                                                               
                                                                                            
  2017   Naykoo      199        401       24         170   5             200    145   56    N
  2015   Krupnova    162        360       41         90    31            83     186   91    Y
  2015   Liu         414        338       230        164   20            177    138   23    Y
  2014   Deng        65         110       26         33    6             62     41    7     Y
  2013   de Mello    144        144       43         75    26            44     73    27    Y
  2012   Li          150        150       93         45    12            98     49    3     Y
  2009   Liang       171        172       129        28    14            112    56    4     Y
  ------ ----------- ---------- --------- ---------- ----- ------------- ------ ----- ----- -----

###### 

Meta-analysis results for the included studies of the association between rs3025039, rs833061, and rs699947 polymorphisms and risk of lung cancer.

  ------------------- ---------------- ---------------------- ------------------ ------------------ -------------------- -------------- --------------- ---------------------- ---------- --------------- ------------------ ---------- --------------- ---------------------- ---------- ---------------
  Variables           No. of studies   Dominant model         Recessive model    Homozygous model   Heterozygous model   Allele model                                                                                                                                                     
                                                                                                                                                                                                                                                                                          
                                       OR (95% CI)            P values           I-squared (%)      OR (95% CI)          P values       I-squared (%)   OR (95% CI)            P values   I-squared (%)   OR (95% CI)        P values   I-squared (%)   OR (95% CI)            P values   I-squared (%)
                                                                                                                                                                                                                                                                                          
  rs3025039 C\>T      +936C/T          (CT + TT) vs. CC       TT vs. (CT + CC)   TT vs. CC          CT vs. CC            T vs. C                                                                                                                                                          
  All                 9                1.12 (0.87-1.46)       \<0.001            76.4               1.25 (0.94-1.65)     0.266          19.9            1.32(0.86-2.04)        0.047      48.9            1.11 (0.86-1.42)   \<0.001    72.1            1.11 (0.89-1.38)       \<0.001    76.2
  Ethnicity                                                                                                                                                                                                                                                                                
   Asian              6                1.17 (0.75-1.81)       \<0.001            84.4               1.37 (0.95-1.97)     0.154          37.9            1.47 (0.78-2.77)       0.022      61.9            1.14 (0.74-1.75)   \<0.001    82              1.15(0.81-1.65)        \<0.001    83.8
   Caucasian          3                1.07 (0.92-1.23)       0.681              0                  1.10 (0.70-1.70)     0.507          0               1.11 (0.71-1.73)       0.488      0               1.07 (0.92-1.24)   0.836      0               1.06 (0.93-1.21)       0.522      0
  Source of control                                                                                                                                                                                                                                                                        
   HB                 3                1.07 (0.92-1.23)       0.681              0                  1.10 (0.70-1.70)     0.507          0               1.11 (0.71-1.73)       0.488      0               1.07(0.92-1.24)    0.836      0               1.06 (0.93-1.21)       0.522      0
   PB                 6                1.17 (0.75-1.81)       \<0.001            84.4               1.37 (0.95-1.97)     0.154          37.9            1.47 (0.78-2.77)       0.022      61.9            1.14 (0.74-1.75)   \<0.001    82              1.15(0.81-1.65)        \<0.001    83.8
  rs833061 C\>T       -460C/T          (CT + TT) vs. CC       TT vs. (CT + CC)   TT vs. CC          CT vs. CC            T vs. C                                                                                                                                                          
  All                 6                1.11(0.97-1.27)        0.534              0                  1.02(0.92-1.13)      0.151          38.2            1.12 (0.96-1.30)       0.269      21.9            1.11 (0.96-1.28)   0.687      0               1.04 (0.97-1.12)       0.201      31.2
  Ethnicity                                                                                                                                                                                                                                                                                
   Asian              4                1.42 (1.07-1.90)       0.991              0                  1.09 (0.94-1.27)     0.085          54.6            **1.51 (1.12-2.03)**   0.821      0               1.34 (0.99-1.81)   0.837      0               **1.12 (1.00-1.26)**   0.184      38
   Caucasian          2                1.03 (0.88-1.20)       0.721              0                  0.96 (0.83-1.11)     0.684          0               1.00 (0.83-1.20)       0.991      0               1.05 (0.89-1.24)   0.616      0               0.99 (0.91-1.09)       0.957      0
  Source of control                                                                                                                                                                                                                                                                        
   HB                 3                1.05 (0.91-1.22)       0.531              0                  0.98 (0.86-1.11)     0.807          0               1.03 (0.87-1.23)       0.532      0               1.07 (0.92-1.26)   0.554      0               1.01 (0.93-1.10)       0.757      0
   PB                 3                **1.45 (1.03-2.06)**   0.968              0                  1.11 (0.93-1.33)     0.039          69.1            **1.59 (1.11-2.29)**   0.708      0               1.33 (0.92-1.91)   0.656      0               1.14 (0.99-1.31)       0.095      57.5
  rsrs699947 C\>A     -2578C/A         (CA + AA) vs. CC       AA vs. (AA + CC)   AA vs. CC          AA vs. CC            A vs. C                                                                                                                                                          
  All                 7                1.33(0.74-2.40)        \<0.001            91.8               0.98(0.52-1.84)      \<0.001        78              1.15(0.71-1.86)        0.037      55.1            1.33 (0.66-2.68)   \<0.001    93.7            1.12 (0.87-1.43)       \<0.001    77.2
  Ethnicity                                                                                                                                                                                                                                                                                
   Asian              5                1.53 (0.67-3.51)       \<0.001            94.3               1.15(0.37-3.52)      \<0.001        84.9            1.50(0.71-3.20)        0.026      63.9            1.48(0.54-4.04)    \<0.001    95.7            1.22 (0.87-1.70)       \<0.001    80.6
   Caucasian          2                0.94(0.68-1.31)        0.654              0                  0.79(0.55-1.13)      0.417          0               0.79 (0.52-1.22)       0.426      0               1.01(0.72-1.42)    0.842      0               0.90 (0.74-1.11)       0.434      0
  Source of control                                                                                                                                                                                                                                                                        
   HB                 3                1.15 (0.75-1.77)       0.122              52.6               0.83 (0.59-1.18)     0.411          0               0.93 (0.56-1.54)       0.247      28.6            1.19(0.82-1.73)    0.224      33.2            1.05 (0.76-1.45)       0.073      61.8
   PB                 4                1.45(0.54-3.90)        \<0.001            95.6               1.09 (0.27-4.34)     \<0.001        88.2            1.43 (0.58-3.54)       0.017      70.4            1.39 (0.42-4.65)   \<0.001    96.7            1.15 (0.79-1.69)       \<0.001    84.3
  ------------------- ---------------- ---------------------- ------------------ ------------------ -------------------- -------------- --------------- ---------------------- ---------- --------------- ------------------ ---------- --------------- ---------------------- ---------- ---------------
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